



## Exploring the Genetic and Epigenetic Factors in Leukemia and Lymphoma

Guest Editor:

**Dr. Francesco E. Boccalatte**  
NYU Grossman School of  
Medicine, New York, NY, USA

Deadline for manuscript  
submissions:

**30 November 2024**

### Message from the Guest Editor

Dear Colleagues,

Advancements in next-generation sequencing, chromatin conformation, and computational tools have deepened our understanding of genetic and epigenetic alterations in cancer. In the field of hematology, these alterations play a vital role in cell identity, differentiation, and transformation. To further our knowledge and develop personalized treatments, we invite you to contribute your original research to our Special Issue. We seek contributions on the molecular drivers of genetic and epigenetic aberrations, as well as strategies for their reversibility. This issue aims to highlight mechanistic approaches, discovery platforms, and diagnostic and therapeutic opportunities. We welcome original research articles and reviews, covering areas such as genetic and epigenetic alterations, gene regulation, computational analysis, and biomarker discovery. For any assistance, please reach out to us. We eagerly await your valuable submissions.

Sincerely,  
Dr. Francesco E. Boccalatte





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)